Teijin Limited (Teijin) And Neurosigma, Inc. (Neurosigma), A Los Angeles-Based Bioelectronics Company Focused On Developing Trigeminal Nerve Stimulation (Tns) Technology For The Treatment Of Neuropsychiatric And Neurological Indications, Today Announced Entering Into A Partnership Based On An Exclusive License Agreement That Grants Teijin Pharma, The Core Company Of Teijin'S Healthcare Business, Exclusive Rights: (I) To Neurosigma'S Tns Patent Rights In Japan Related To Attention Deficit Hyperactivity Disorder (Adhd) And (Ii) To Market The Monarch Etns System
